Tetraspanin CD9 is Regulated by MiR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Apr 1

PMID 32224917

Citations 10

Authors

Danielle R Bond

Richard Kahl

Joshua S Brzozowski

Helen Jankowski

Crystal Naudin

Mamta Pariyar

Kelly A Avery-Kiejda

Christopher J Scarlett

Claude Boucheix

William J Muller

Leonie K Ashman

Murray J Cairns

Severine Roselli

Judith Weidenhofer

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most commonly diagnosed and the second leading cause of cancer-related mortality among women worldwide. miR-518f-5p has been shown to modulate the expression of the metastasis suppressor CD9 in prostate cancer. However, the role of miR-518f-5p and CD9 in breast cancer is unknown. Therefore, this study aimed to elucidate the role of miR-518f-5p and the mechanisms responsible for decreased CD9 expression in breast cancer, as well as the role of CD9 in de novo tumor formation and metastasis. miR-518f-5p function was assessed using migration, adhesion, and proliferation assays. miR-518f-5p was overexpressed in breast cancer cell lines that displayed significantly lower CD9 expression as well as less endogenous CD9 3'UTR activity, as assessed using qPCR and dual luciferase assays. Transfection of miR-518f-5p significantly decreased CD9 protein expression and increased breast cell migration in vitro. Cd9 deletion in the MMTV/PyMT mouse model impaired tumor growth, but had no effect on tumor initiation or metastasis. Therefore, inhibition of miR-518f-5p may restore CD9 expression and aid in the treatment of breast cancer metastasis.

Citing Articles

Multiparametric profiling of HER2-enriched extracellular vesicles in breast cancer using Single Extracellular VEsicle Nanoscopy.

Jiang N, Saftics A, Romano E, Ghaeli I, Resto C, Robles V J Nanobiotechnology. 2024; 22(1):589.

PMID: 39342336 PMC: 11438238. DOI: 10.1186/s12951-024-02858-x.

Tspan protein family: focusing on the occurrence, progression, and treatment of cancer.

Zhang H, Song Q, Shang K, Li Y, Jiang L, Yang L Cell Death Discov. 2024; 10(1):187.

PMID: 38649381 PMC: 11035590. DOI: 10.1038/s41420-024-01961-0.

Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.

Tang Z, Liu L, Borlak J Clin Epigenetics. 2023; 15(1):89.

PMID: 37208732 PMC: 10199547. DOI: 10.1186/s13148-023-01500-1.

MiR-146a rs2910164 (G/C) polymorphism is associated with the development and prognosis of acute coronary syndromes: an observational study including case control and validation cohort.

Qiao X, Zheng T, Xie Y, Yao X, Yuan Z, Wu Y J Transl Med. 2023; 21(1):325.

PMID: 37189131 PMC: 10186648. DOI: 10.1186/s12967-023-04140-4.

The versatile roles of testrapanins in cancer from intracellular signaling to cell-cell communication: cell membrane proteins without ligands.

Zhou Z, Yang Z, Zhou L, Yang M, He S Cell Biosci. 2023; 13(1):59.

PMID: 36941633 PMC: 10025802. DOI: 10.1186/s13578-023-00995-8.

References

Rappa G, Green T, Karbanova J, Corbeil D, Lorico A . Tetraspanin CD9 determines invasiveness and tumorigenicity of human breast cancer cells. Oncotarget. 2015; 6(10):7970-91. PMC: 4480729. DOI: 10.18632/oncotarget.3419. View

Castro-Sanchez L, Soto-Guzman A, Navarro-Tito N, Martinez-Orozco R, Salazar E . Native type IV collagen induces cell migration through a CD9 and DDR1-dependent pathway in MDA-MB-231 breast cancer cells. Eur J Cell Biol. 2010; 89(11):843-52. DOI: 10.1016/j.ejcb.2010.07.004. View

Remsik J, Fedr R, Navratil J, Bino L, Slabakova E, Fabian P . Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer. Br J Cancer. 2018; 118(6):813-819. PMC: 5886127. DOI: 10.1038/bjc.2017.497. View

Hwang J, Jo K, Lee Y, Sung B, Park Y, Lee J . Upregulation of CD9 in ovarian cancer is related to the induction of TNF-α gene expression and constitutive NF-κB activation. Carcinogenesis. 2011; 33(1):77-83. DOI: 10.1093/carcin/bgr257. View

Calaluce R, Gubin M, Davis J, Magee J, Chen J, Kuwano Y . The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer. BMC Cancer. 2010; 10:126. PMC: 2856550. DOI: 10.1186/1471-2407-10-126. View

Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J . Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res. 2005; 11(12):4357-64. DOI: 10.1158/1078-0432.CCR-04-2107. View

Kwon H, Choi J, Kang S, Son Y, Bae Y . Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma. Histopathology. 2017; 70(7):1155-1165. DOI: 10.1111/his.13184. View

Zhan T, Rindtorff N, Boutros M . Wnt signaling in cancer. Oncogene. 2016; 36(11):1461-1473. PMC: 5357762. DOI: 10.1038/onc.2016.304. View

Kischel P, Bellahcene A, Deux B, Lamour V, Dobson R, De Pauw E . Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Res. 2012; 32(12):5211-20. View

10.

Hromadnikova I, Kotlabova K, Ondrackova M, Pirkova P, Kestlerova A, Novotna V . Expression profile of C19MC microRNAs in placental tissue in pregnancy-related complications. DNA Cell Biol. 2015; 34(6):437-57. PMC: 4486149. DOI: 10.1089/dna.2014.2687. View

11.

Copeland B, Bowman M, Boucheix C, Ashman L . Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner. Int J Cancer. 2013; 133(8):1803-12. DOI: 10.1002/ijc.28204. View

12.

Lambert A, Ozturk S, Thiagalingam S . Integrin signaling in mammary epithelial cells and breast cancer. ISRN Oncol. 2012; 2012:493283. PMC: 3317013. DOI: 10.5402/2012/493283. View

13.

Nana-Sinkam S, Croce C . MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. Genome Biol. 2014; 15(9):445. PMC: 4709998. DOI: 10.1186/s13059-014-0445-8. View

14.

Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D . PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. 2016; 45(D1):D183-D189. PMC: 5210595. DOI: 10.1093/nar/gkw1138. View

15.

Castaneda-Gill J, Vishwanatha J . Antiangiogenic mechanisms and factors in breast cancer treatment. J Carcinog. 2016; 15:1. PMC: 4785777. DOI: 10.4103/1477-3163.176223. View

16.

Zoller M . Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2008; 9(1):40-55. DOI: 10.1038/nrc2543. View

17.

Pellinen T, Rantala J, Arjonen A, Mpindi J, Kallioniemi O, Ivaska J . A functional genetic screen reveals new regulators of β1-integrin activity. J Cell Sci. 2012; 125(Pt 3):649-61. DOI: 10.1242/jcs.090704. View

18.

Murayama Y, Oritani K, Tsutsui S . Novel CD9-targeted therapies in gastric cancer. World J Gastroenterol. 2015; 21(11):3206-13. PMC: 4363749. DOI: 10.3748/wjg.v21.i11.3206. View

19.

Agnoli C, Grioni S, Pala V, Allione A, Matullo G, Di Gaetano C . Biomarkers of inflammation and breast cancer risk: a case-control study nested in the EPIC-Varese cohort. Sci Rep. 2017; 7(1):12708. PMC: 5629213. DOI: 10.1038/s41598-017-12703-x. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View